Acebilustat (CTX-4430) is an oral anti-inflammatory drug that reduces production of leukotriene B4 (LTB4), a molecule that leads to inflammation and is known to be elevated in people with CF. Reduction of inflammation helps prevent permanent tissue damage in the lungs.

Status

 A phase 2 study of Acebilustat did not meet its primary endpoint. No further development in CF is planned.

Sponsor

This program was sponsored by Celtaxsys and partially funded by the Cystic Fibrosis Foundation. It was conducted within the Therapeutics Development Network.